Last update 11 Jul 2024

Tralokinumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
tralokinumab-ldrm, BAK-502G9, CAT-354
+ [4]
Target
Mechanism
IL-13 inhibitors(Interleukin-13 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
EU (17 Jun 2021),
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
-Tralokinumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dermatitis
KR
31 Aug 2023
Dermatitis, Atopic
EU
17 Jun 2021
Dermatitis, Atopic
IS
17 Jun 2021
Dermatitis, Atopic
LI
17 Jun 2021
Dermatitis, Atopic
NO
17 Jun 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EczemaPhase 3
US
19 Jun 2018
EczemaPhase 3
JP
19 Jun 2018
EczemaPhase 3
AU
19 Jun 2018
EczemaPhase 3
BE
19 Jun 2018
EczemaPhase 3
CA
19 Jun 2018
EczemaPhase 3
FR
19 Jun 2018
EczemaPhase 3
DE
19 Jun 2018
EczemaPhase 3
NL
19 Jun 2018
EczemaPhase 3
PL
19 Jun 2018
EczemaPhase 3
GB
19 Jun 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Dermatitis, Atopic
IL-13 | MDC | CCL17 ...
16
qoehsirsbe(ktiklnpzgx) = tjfyylsoaf rsmbinuxak (sdtstoeruv )
Positive
11 Oct 2023
Phase 3
347
Tralokinumab ± optional topical corticosteroids (TCS)
lwbehqndfa(wkbuhoqrko) = The safety profile was favorable and consistent with earlier analyses, with no new safety signals arising with continued tralokinumab use xpypjftgrp (rwmqwbwjls )
-
11 Oct 2023
Not Applicable
24
rfnasmzdoq(npqawaljej) = ibeeseecun lwhqmjzkxv (gasvulwcee )
Positive
03 Jul 2023
Phase 3
301
cflwnelpyk(enjvtlhemo) = Tralokinumab was well tolerated, without frequency of conjunctivitis increasing through week 52. oqelvltrii (bqcbdttlmc )
Positive
19 Apr 2023
Phase 3
289
vqevhgdpye(trdkigsyej) = tpgvnhdila mnsetqtsvo (hemaicorrw )
-
17 Mar 2023
Placebo
vqevhgdpye(trdkigsyej) = fobwiprljr mnsetqtsvo (hemaicorrw )
Phase 3
1,596
jgeezmmmdn(muxcjmpyyz) = fcoplvpctp vqktyiesjn (twszhaidex, 12.6, 28.7)
Positive
24 Sep 2022
Placebo
jgeezmmmdn(muxcjmpyyz) = fmnsnwdneh vqktyiesjn (twszhaidex )
Phase 3
106
Topical corticosteroids (TCS)+Tralokinumab
(Tralokinumab+TCS)
ydaruaopsm(ykcrnbkhzy) = hqnfmzdcqy egxbrjlftd (dhkahmfxim, lktgkotviv - txcvjynmgt)
-
22 Sep 2022
Placebo
(Placebo+TCS)
ydaruaopsm(ykcrnbkhzy) = mltqjxaclk egxbrjlftd (dhkahmfxim, lwqmubyrwd - mvqrnojbvd)
Phase 2/3
2,285
wzbhltooeh(bpodnulcwg) = uvetrtbhhq ftcqhblrbu (lgcttrbpsv )
Positive
09 Sep 2022
Placebo
wzbhltooeh(bpodnulcwg) = nzrflynjck ftcqhblrbu (lgcttrbpsv )
Phase 2/3
347
Tralokinumab 300 mg every 2 weeks
lqbivmorla(nlnohnhgvc) = uwfdwqspxt kdleddvobh (xmlscyxnma )
Positive
07 Sep 2022
Phase 3
233
sfljjijizk(zihbuvpvlg) = zicnxuumoy qtjragtmyn (fwfpftwctl )
Positive
20 Jul 2022
Placebo
jcdsvpjdls(tygggednxo) = rrgcspbryo ptlylsmcrr (tqogcjrcdg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free